External quality assurance of HER2 FISH and ISH testing three years of the UK national external quality assurance scheme

John M S Bartlett, Merdol Ibrahim, Bharat Jasani, John M. Morgan, Ian Ellis, Elaine Kay, Yvonne Connolly, Fiona Campbell, Anthony O'Grady, Sarah Barnett, Keith Miller

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The American Society of Clinical Oncology/College of American Pathologists guidelines highlighted the critical importance of quality assurance in diagnostic testing for HER2. Unstained formalin-fixed, paraffin-embedded human breast carcinoma cell line sections were circulated to scheme participants on 9 occasions. "Reference laboratories " reported results for the HER2/chromosome 17 ratio and HER2 copy number for 3 years for each cell line, including 418 sets of results (1,671 results total). The number of participants was 62 laboratories in the final analysis. The mean and SD of results from reference laboratories demonstrated consistency during the 3-year period. The percentage of laboratories achieving "appropriate" results ranged from 45% to 88%, and the percentage achieving "inappropriate" results ranged from 5% to 29%. No consistent effect of the HER2 in situ hybridization testing method was demonstrated. Participation in external quality assurance schemes is a valuable mechanism for demonstrating and acquiring consistency for HER2 testing by in situ hybridization. Poor performance can be corrected via assistance and advice.

Original languageEnglish
Pages (from-to)106-111
Number of pages6
JournalAmerican Journal of Clinical Pathology
Volume131
Issue number1
DOIs
Publication statusPublished - Jan 2009
Externally publishedYes

Fingerprint

In Situ Hybridization
Cell Line
Chromosomes, Human, Pair 17
Paraffin
Formaldehyde
Guidelines
Breast Neoplasms
Pathologists

Keywords

  • Fluorescence in situ hybridization
  • Gene copy number
  • Gene/chromosome ratio
  • HER2
  • In situ hybridization
  • Practice guidelines
  • Quality assurance

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

External quality assurance of HER2 FISH and ISH testing three years of the UK national external quality assurance scheme. / Bartlett, John M S; Ibrahim, Merdol; Jasani, Bharat; Morgan, John M.; Ellis, Ian; Kay, Elaine; Connolly, Yvonne; Campbell, Fiona; O'Grady, Anthony; Barnett, Sarah; Miller, Keith.

In: American Journal of Clinical Pathology, Vol. 131, No. 1, 01.2009, p. 106-111.

Research output: Contribution to journalArticle

Bartlett, JMS, Ibrahim, M, Jasani, B, Morgan, JM, Ellis, I, Kay, E, Connolly, Y, Campbell, F, O'Grady, A, Barnett, S & Miller, K 2009, 'External quality assurance of HER2 FISH and ISH testing three years of the UK national external quality assurance scheme', American Journal of Clinical Pathology, vol. 131, no. 1, pp. 106-111. https://doi.org/10.1309/AJCPLN78ZQXEMNMA
Bartlett, John M S ; Ibrahim, Merdol ; Jasani, Bharat ; Morgan, John M. ; Ellis, Ian ; Kay, Elaine ; Connolly, Yvonne ; Campbell, Fiona ; O'Grady, Anthony ; Barnett, Sarah ; Miller, Keith. / External quality assurance of HER2 FISH and ISH testing three years of the UK national external quality assurance scheme. In: American Journal of Clinical Pathology. 2009 ; Vol. 131, No. 1. pp. 106-111.
@article{4c646e3722114633bd41639d054a30ac,
title = "External quality assurance of HER2 FISH and ISH testing three years of the UK national external quality assurance scheme",
abstract = "The American Society of Clinical Oncology/College of American Pathologists guidelines highlighted the critical importance of quality assurance in diagnostic testing for HER2. Unstained formalin-fixed, paraffin-embedded human breast carcinoma cell line sections were circulated to scheme participants on 9 occasions. {"}Reference laboratories {"} reported results for the HER2/chromosome 17 ratio and HER2 copy number for 3 years for each cell line, including 418 sets of results (1,671 results total). The number of participants was 62 laboratories in the final analysis. The mean and SD of results from reference laboratories demonstrated consistency during the 3-year period. The percentage of laboratories achieving {"}appropriate{"} results ranged from 45{\%} to 88{\%}, and the percentage achieving {"}inappropriate{"} results ranged from 5{\%} to 29{\%}. No consistent effect of the HER2 in situ hybridization testing method was demonstrated. Participation in external quality assurance schemes is a valuable mechanism for demonstrating and acquiring consistency for HER2 testing by in situ hybridization. Poor performance can be corrected via assistance and advice.",
keywords = "Fluorescence in situ hybridization, Gene copy number, Gene/chromosome ratio, HER2, In situ hybridization, Practice guidelines, Quality assurance",
author = "Bartlett, {John M S} and Merdol Ibrahim and Bharat Jasani and Morgan, {John M.} and Ian Ellis and Elaine Kay and Yvonne Connolly and Fiona Campbell and Anthony O'Grady and Sarah Barnett and Keith Miller",
year = "2009",
month = "1",
doi = "10.1309/AJCPLN78ZQXEMNMA",
language = "English",
volume = "131",
pages = "106--111",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "1",

}

TY - JOUR

T1 - External quality assurance of HER2 FISH and ISH testing three years of the UK national external quality assurance scheme

AU - Bartlett, John M S

AU - Ibrahim, Merdol

AU - Jasani, Bharat

AU - Morgan, John M.

AU - Ellis, Ian

AU - Kay, Elaine

AU - Connolly, Yvonne

AU - Campbell, Fiona

AU - O'Grady, Anthony

AU - Barnett, Sarah

AU - Miller, Keith

PY - 2009/1

Y1 - 2009/1

N2 - The American Society of Clinical Oncology/College of American Pathologists guidelines highlighted the critical importance of quality assurance in diagnostic testing for HER2. Unstained formalin-fixed, paraffin-embedded human breast carcinoma cell line sections were circulated to scheme participants on 9 occasions. "Reference laboratories " reported results for the HER2/chromosome 17 ratio and HER2 copy number for 3 years for each cell line, including 418 sets of results (1,671 results total). The number of participants was 62 laboratories in the final analysis. The mean and SD of results from reference laboratories demonstrated consistency during the 3-year period. The percentage of laboratories achieving "appropriate" results ranged from 45% to 88%, and the percentage achieving "inappropriate" results ranged from 5% to 29%. No consistent effect of the HER2 in situ hybridization testing method was demonstrated. Participation in external quality assurance schemes is a valuable mechanism for demonstrating and acquiring consistency for HER2 testing by in situ hybridization. Poor performance can be corrected via assistance and advice.

AB - The American Society of Clinical Oncology/College of American Pathologists guidelines highlighted the critical importance of quality assurance in diagnostic testing for HER2. Unstained formalin-fixed, paraffin-embedded human breast carcinoma cell line sections were circulated to scheme participants on 9 occasions. "Reference laboratories " reported results for the HER2/chromosome 17 ratio and HER2 copy number for 3 years for each cell line, including 418 sets of results (1,671 results total). The number of participants was 62 laboratories in the final analysis. The mean and SD of results from reference laboratories demonstrated consistency during the 3-year period. The percentage of laboratories achieving "appropriate" results ranged from 45% to 88%, and the percentage achieving "inappropriate" results ranged from 5% to 29%. No consistent effect of the HER2 in situ hybridization testing method was demonstrated. Participation in external quality assurance schemes is a valuable mechanism for demonstrating and acquiring consistency for HER2 testing by in situ hybridization. Poor performance can be corrected via assistance and advice.

KW - Fluorescence in situ hybridization

KW - Gene copy number

KW - Gene/chromosome ratio

KW - HER2

KW - In situ hybridization

KW - Practice guidelines

KW - Quality assurance

UR - http://www.scopus.com/inward/record.url?scp=58549119992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58549119992&partnerID=8YFLogxK

U2 - 10.1309/AJCPLN78ZQXEMNMA

DO - 10.1309/AJCPLN78ZQXEMNMA

M3 - Article

VL - 131

SP - 106

EP - 111

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 1

ER -